Acadia Healthcare Company, Inc.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides our repurchases of shares of our common stock during the three months ended March 31, 2026:
| Period | Total Numberof SharesPurchased (a) | Average PricePaid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Numberof Shares thatMay Yet Be Purchased Underthe Plansor Programs (in millions) (b) |
|---|---|---|---|---|
| January 1 - January 31 | 777 | $13.46 | — | $250.0 |
| February 1 - February 28 | 39,461 | 19.29 | — | $250.0 |
| March 1 - March 31 | 105,065 | 24.26 | — | $250.0 |
| Total | 145,303 | |||
(a)
There were no shares repurchased during the three months ended March 31, 2026 under the Share Repurchase Program, and there were 145,303 shares withheld in connection with tax payments due upon vesting of employee restricted stock awards and the use of shares of our common stock to pay the exercise price of employee stock options.
(b)
We may repurchase up to $300.0 million of our common stock under the Share Repurchase Program announced on February 25, 2025. As of March 31, 2026, $250.0 million remained available for purchase under the Share Repurchase Program. The Share Repurchase Program has no termination date and may be modified, suspended or discontinued by the Company’s board of directors at any time.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.